Skip to main content

Table 4 The concordance study between GeneReader, MiSeq, Pyrosequencingand Therascreen PCR assays

From: Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform

Sample no. KRAS AA change KRAS variant allele fraction (%)
Therascreen PCR/Pyro GeneReadera MiSeqa
1 G12D + 21 7
2 G12D + 39 12
3 A59T 19 15 14
4 G13D + 41 15
5 G12D + 45 11
6 Q61H 14 9 13
7 A146P 41 40 32
8 Q61H 36 35 26
9 Q61H 32 22 35
10 K117 N 24 34 39
11 G13D + 47 15
12 G12C + 32 10
13 G13D + 39 10
14 Q61H 26 21 23
  1. +: Variant identified by Therascreen PCR; allele fraction not available
  2. a: Sample processed from different FFPE section with potentially different tumor content and variant allele fraction